Illumina and D3b announce partnership for research in pediatric diseases

Illumina (ILMN) and the Center for Data-Driven Discovery in Biomedicine, or D3b, announced a data partnership to advance research in pediatric cancer and rare disease. Through cloud-based data platforms, the global research community can unify and analyze pediatric data within a single, scalable discovery environment, enabling real-time, cross-cohort analysis and accelerating translation to clinical care. Through this initiative, D3b is analyzing 100,000 whole genomes from pediatric patients using Illumina software solutions. This is one of the largest unified genomic datasets ever assembled. D3b and Illumina are enabling discovery at a scale not previously possible, making the resulting insights available through the Gabriella Miller Kids First Data Resource Center. This data empowers researchers and clinicians to uncover the biological origins of rare disease and cancer and translate findings for pediatric precision medicine. The dataset will include whole genomes from patients with rare congenital conditions and cancers, collected through federally-funded programs, including the Kids First DRC and the Children’s Brain Tumor Network. The samples are being analyzed with DRAGEN v4.4 and Illumina Connected Analytics to create a comprehensive dataset with the accuracy, speed, and scale necessary for meaningful, cross-sample insights.